齐拉西酮合并丁螺环酮治疗精神分裂症的对照研究

目的：探讨齐拉西酮合并丁螺环酮治疗精神分裂症的疗效和安全性。方法：将112例符合CCMD-3诊断标准的精神分裂症患者随机均分为两组,研究组给予齐拉西酮合并丁螺环酮治疗,对照组单独给予齐拉西酮治疗,疗程8周。分别于治疗前和治疗后2、4、6、8周末采用阳性症状和阴性症状量表（PANSS）评定临床疗效,副反应量表（TESS）评定副反应。结果：治疗8周后,研究组和对照组的有效率差异无统计学意义（P〉0.05）;对照组的副反应心动过速、锥体外系反应、静坐不能发生率显著高于研究组（P〈0.05）。结论：齐拉西酮合并丁螺环酮治疗精神分裂症患者的疗效较好,副作用较小,值得推广。

Contrast study of ziprasidone combined with buspirone in treatment of schizophrenia

Objective： To study the efficacy and safety of ziprasidone combined with buspirone in the treatment of schizophrenia.Methods： 112 patients with schizophrenia by CCMD-3 were randomly allocated to treatment group and control group,treated respectively with ziprasidone combined with buspirone or with ziprasidone alone for 8 weeks.The PANSS and TESS were employed to evaluate the efficacy and adverse effects respectively before and at the ends of 2,4,6,and 8 weeks′ treatment.Results： The total effective rates for the treatment group and control group were similar after the 8-week treatment.There was no significant difference between the two groups.Incidence of adverse effects,such as tachycardia,extrapyramidal reactions and akathisia,was significantly lower in the treatment group than in the control group（P0.05）.Conclusion： Ziprasidone combined with buspirone has similar efficacy but fewer side effects in the treatment of schizophrenia.